Kaftrio

Tezacaftor/Elexacaftor/Ivacaftor, the active ingredient in Kaftrio, is a CFTR modulator presented as a 100 mg elexacaftor / 50 mg tezacaftor / 75 mg ivacaftor oral tablet for oral use. It treats cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.

GNH USA supplies Kaftrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kaftrio is a CFTR modulator indicated for cystic fibrosis, a genetic disorder that impairs chloride transport.

- Cystic fibrosis (patients ≥ 12 years with at least one F508del mutation): improves lung function, reduces pulmonary exacerbations, and supports better nutritional status.

Kaftrio may cause a range of adverse reactions. Patients should be aware of both common and less frequent but serious events.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, may be transient. - Nausea: occasional, often resolves with continued therapy. - Abdominal pain: cramping or discomfort. - Rash: skin redness or itching. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Hepatic injury: significant elevation of liver enzymes or bilirubin. - Cataracts: lens opacity requiring ophthalmologic monitoring. - Severe allergic reaction: anaphylaxis, angioedema, or urticaria. - Pulmonary hemorrhage: rare bleeding in the lungs. - Elevated serum creatinine: possible renal function impact. - Myopathy: muscle weakness or pain, rarely reported.

Before initiating Kaftrio, clinicians should evaluate several safety considerations.

- Monitor liver function: obtain baseline ALT/AST and repeat periodically. - Assess for cataracts: schedule annual ophthalmologic examinations. - Avoid in severe hepatic impairment: contraindicated in patients with advanced liver disease. - Pregnancy and lactation: discuss potential risks with the patient; safety data are limited. - Review concomitant medications: evaluate for interactions that may affect drug exposure. - Store at ambient temperature: keep below 25 °C, protect from moisture, and retain in the original packaging.

Kaftrio interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine): may markedly reduce Kaftrio exposure. - Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole): may substantially increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Digoxin: potential increase in serum levels; observe for signs of toxicity. - Oral contraceptives: reduced efficacy reported; consider alternative contraception.